Heparin-induced thrombocytopenia: The role of platelets genetic polymorphisms

Platelets

Volumn 24, Issue 5, 2013, Pages 362-368

  Pamela, Scarparo ^a   Anna Maria, Lombardi ^a   Elena, Duner ^a   Giovanni, Malerba ^b   Emanuele, Allemand ^a   Silvia, Vettore ^a   Carmen, Blumentritt ^c   Andreas, Greinacher ^c   Fabrizio, Fabris ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Heparin; Polymorphism; Thrombocytopenia; Thrombosis

Indexed keywords

HEPARIN; IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

AGED; ANTIBODIES; ANTICOAGULANTS; ANTIGENS, CD31; ANTIGENS, HUMAN PLATELET; BLOOD PLATELETS; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HEPARIN; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; PLATELET FACTOR 4; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; RECEPTORS, IGG; THROMBOCYTOPENIA;

EID: 84879746342     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2012.701026     Document Type: Article

References (39)

1. Warkentin TE, Poncz M, Cines DB. Heparin-induced thrombocytopenia. In: Gerson SL and High KA, editors. Clinical Haematology. Vol. 1. Philadelphia: Elsevier; 2006. pp 887-900
2. Prandoni P, Siragusa S, Girolami B, Fabris F. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: A prospective cohort study. Blood 2005;106:3049-3054
3. Carlsson LE, Lubenow N, Blumentritt C, Kempf R, Papenberg S, Shroder W, Eichler P, Herrmann FH, Santoso S, Greinacher A. Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics 2003;13:253-258
4. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: Recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:311s-337s.
5. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: Toward consensus. Thromb Haemost 1998;79:1-7
6. Gruel Y, Pouplard C, Dominique L, Charlotte M-B, Chloé C, Hervé W. The homozygous Fc-RIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. Blood 2004;104:2791-2793
7. Davenport A. Antibodies to heparin-platelet factor 4 complex: Pathogenesis, epidemiology and management of HIT in haemodialysis. Am J Kidney Dis 2009;54:361-374
8. Amiral J, Marfaing-Koka A, Poncz M, Meyer D. The biological basis of immune heparin-induced thrombocytopenia. Platelets 1998;9:77-91
9. Karassa FB, Trikalinos TA, Ioannidis JPA. The role of Fc-RIIA and Fc-RIIIA polymorphism in autoimmune disease. Biomed Pharmacother 2004;58:286-291
10. Trikalinos TA, Karassa FB, Ioannidis JP. Meta-analysis of the association between low-affinity Fcgamma receptor gene polymorphisms and hematologic and autoimmune disease. Blood 2001;98:1634-1635
11. Feng D, Lindpaintner K, Larson MG, Rao VS, O'Donnell CJ, Lipinska I, Schmitz C, Sutherland PA, Silbershatz H, D'Agostino RB, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: The Framingham offspring study. Arterioscler Thromb Vasc Biol 1999;19:1142-1147
12. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090-1094
13. Harris K, Nguyen P, van Cott EM. Platelet PlA2 polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia. Am J Clin Pathol. 2008;129:282-286
14. Sullam PM, Hyun WC, Szöllösi J, Dong J, Foss WM, López JA. Physical proximity and functional interplay of the glycoprotein Ib-IX-V complex and the Fc receptor FcgammaRIIA on the platelet plasma membrane. J Biol Chem 1998;273:5331-5336
15. Thai L, Ashman L, Harbour SN. Physical proximity and functional interplay of PECAM-1 with the Fc receptor Fc gamma RIIa on the platelet plasma membrane. Blood 2003;102:3637-3645
16. Kroll H, Sun Q, Santoso S. Platelet endothelial cell adhesion molecule-1(PECAM-1) is a target in drug-induced thrombocytopenia. Blood 2000;96:1409-1414
17. Elrayess MA, Webb KE, Bellingan GJ, Whittall RA, Kabir J, Hawe E, Syvanne M, Taskinen MR, Frick MH, Nieminen MS, et al. R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events. Atherosclerosis 2004;177:127-135
18. Fujimoto TT, Inoue M, Shimomura T, Fujimura K. Involvement of Fc- receptor polymorphism in the therapeutic response of idiopathic thrombocytopenic purpura. Br J Haematol 2001;115:125-130
19. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc(gamma)RIIIa-158 V/V and V/F polymorphism. Blood 2007;110:2561-2564
20. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48 L/R/H phenotype. Blood 1997;90:1109-1114
21. Salmon JE, Pricop L. Human receptors for immunoglobulin G. Arthrit Rheumat 2001;44:739-750
22. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-765
23. Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A. Incidence and clinical significance of anti-PF4/ heparin antibodies of the IgG, IgM and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006;76:420-426
24. Warkentin TE, Sheppard J, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurement using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008;6:1304-1312
25. Eichler P, Budde U, Haas S, Kroll H, Loreth RM, Meyer O, Pachmann U, Pötzsch B, Schabel A, Albrecht D, et al. First workshop for detection of heparin-induced antibodies: Validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost 1999;81:625-629
26. Gulen F, Tanac R, Altinoz S, Berdeli A, Zeyrek D, Koksoy H, Demir E. The Fc gammaRIIa polymorphism in Turkish children with bronchial asthma and allergic rhinitis. Clin Biochem 2007;40:392-396
27. Gavasso S, Nygard O, Pedersen ER, Aarseth JH, Bleie O, Myhr KM, Vedeler CA. Fc- receptor IIIA polymorphism as a risk factor for coronary artery disease. Atherosclerosis 2005;180:277-282
28. Bu FX, Armas L, Lappe J, Zhou Y, Gao G, Wang HW, Recker R, Zhao LJ. Comprehensive association analysis of nine candidate genes with serum 25-hydroxy vitamin D levels among healthy Caucasian subjects. Hum Genet 2010;128:549-556
29. R Development Core Team. 2010. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: URL http://www.Rproject. Org
30. Bontadini A, Tazzari PL, Manfroi S, Ruscitto MC, Fruet F, Conte R. Human platelet antigen and neutrophil antigen gene frequency in the Italian population determined by polymerase chain reaction with sequence-specific primers. Haematologica 2000;85:430-431
31. Grumet FC, Hiraki DD, Brown BW, Zehnder JL, Zacks ES, Draksharapu A, Parnes J, Negrin RS. CD31 Mismatching affects marrow transplantation outcome. Biol Blood Marrow Transplant 2001;7:503-512
32. Reilly MP, Taylor SM, Hartmen NK, Arepally GM, Sachais BS, Cines DB, Poncz M, McKenzie SE. Heparin induced thrombocytopenia/ thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood 2001;98:2442-2447
33. Fabris F, Luzzatto G, Soini B, Ramon R, Scandellari R, Randi ML, Girolami A. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J Intern Med 2002;252:149-154
34. Brandt JT, Isenhart CE, Osborne JM, Ahmed A, Anderson CL. On the role of platelet Fc gamma RIIa phenotype in heparininduced thrombocytopenia. Thromb Haemost 1995;74:1564-1572
35. Denomme GA, Warkentin TE, Horsewood P, Sheppard JI, Warner MN, Kelton JG. Activation of platelets by sera containing IgG1 heparin-dependent antibodies: An explanation for the predominance of Fc-RIIa ''low responders'' (His 131) in patients with heparin-induced thrombocytopenia. J Lab Clin Med 1997;130:278-284
36. Arepally G, McKenzie SE, Jang XM, Poncz M, Cines DB. Fc-RIIA H/R 131 polymorphism, subclass specific IgG anti heparin/PF4 antibodies and clinical course in patients with HIT. Blood 1997;89:370-375
37. Carlsson LE, Santoso S, Baurichter G, Kroll H, Papenberg S, Eichler P, Westerdaal NA, Kiefel V, van de Winkel JG, Greinacher A. Heparin-induced thrombocytopenia: New insights into the impact of the FcgammaRIIa-R-H131 polymorphism. Blood 1998;92:1526-1531
38. Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: Clinical implications for heparin-induced thrombocytopenia. Circulation 1999;99:2530-2536
39. Manger K, Repp R, Spriewald B, Rascu A, Geiger A, Wassmuth R, Westerdaal N, Wentz B, Manger B, Kalden J, et al. Fc gamma receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: Association with clinical symptoms. Arthritis Rheum 1998;41:1181-1189